Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
7,711
archived clinical trials in
Depression

AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated:  7/16/2012
713
mi
from 43215
Gainsville, FL
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated: 7/16/2012
Clinical Research Facility
713
mi
from 43215
Gainsville, FL
Click here to add this to my saved trials
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated:  7/16/2012
976
mi
from 43215
Hollywood, FL
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated: 7/16/2012
Clinical Research Facility
976
mi
from 43215
Hollywood, FL
Click here to add this to my saved trials
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated:  7/16/2012
668
mi
from 43215
Jacksonville, FL
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated: 7/16/2012
Clinical Research Facility
668
mi
from 43215
Jacksonville, FL
Click here to add this to my saved trials
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated:  7/16/2012
436
mi
from 43215
Atlanta, GA
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated: 7/16/2012
Clinical Research Facility
436
mi
from 43215
Atlanta, GA
Click here to add this to my saved trials
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated:  7/16/2012
416
mi
from 43215
Roswell, GA
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated: 7/16/2012
Clinical Research Facility
416
mi
from 43215
Roswell, GA
Click here to add this to my saved trials
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated:  7/16/2012
301
mi
from 43215
Hoffman Estates, IL
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated: 7/16/2012
Clinical Research Facility
301
mi
from 43215
Hoffman Estates, IL
Click here to add this to my saved trials
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated:  7/16/2012
288
mi
from 43215
Joliet, IL
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated: 7/16/2012
Clinical Research Facility
288
mi
from 43215
Joliet, IL
Click here to add this to my saved trials
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated:  7/16/2012
624
mi
from 43215
Overland Park, KA
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated: 7/16/2012
Clinical Research Facility
624
mi
from 43215
Overland Park, KA
Click here to add this to my saved trials
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated:  7/16/2012
884
mi
from 43215
Lake Charles, LA
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated: 7/16/2012
Clinical Research Facility
884
mi
from 43215
Lake Charles, LA
Click here to add this to my saved trials
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated:  7/16/2012
789
mi
from 43215
Shreveport, LA
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated: 7/16/2012
Clinical Research Facility
789
mi
from 43215
Shreveport, LA
Click here to add this to my saved trials
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated:  7/16/2012
648
mi
from 43215
Haverhill, MA
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated: 7/16/2012
Clinical Research Facility
648
mi
from 43215
Haverhill, MA
Click here to add this to my saved trials
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated:  7/16/2012
395
mi
from 43215
St. Louis, MO
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated: 7/16/2012
Clinical Research Facility
395
mi
from 43215
St. Louis, MO
Click here to add this to my saved trials
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated:  7/16/2012
430
mi
from 43215
Willingboro, NJ
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated: 7/16/2012
Clinical Research Facility
430
mi
from 43215
Willingboro, NJ
Click here to add this to my saved trials
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated:  7/16/2012
1333
mi
from 43215
Albuquerque, NM
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated: 7/16/2012
Clinical Research Facility
1333
mi
from 43215
Albuquerque, NM
Click here to add this to my saved trials
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated:  7/16/2012
355
mi
from 43215
Rochester, NY
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated: 7/16/2012
Clinical Research Facility
355
mi
from 43215
Rochester, NY
Click here to add this to my saved trials
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated:  7/16/2012
418
mi
from 43215
East Stroudsburg, PA
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated: 7/16/2012
Clinical Research Facility
418
mi
from 43215
East Stroudsburg, PA
Click here to add this to my saved trials
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated:  7/16/2012
416
mi
from 43215
Philadelphia, PA
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated: 7/16/2012
Clinical Research Facility
416
mi
from 43215
Philadelphia, PA
Click here to add this to my saved trials
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated:  7/16/2012
1069
mi
from 43215
Austin, TX
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated: 7/16/2012
Clinical Research Facility
1069
mi
from 43215
Austin, TX
Click here to add this to my saved trials
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated:  7/16/2012
910
mi
from 43215
Dallas, TX
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated: 7/16/2012
Clinical Research Facility
910
mi
from 43215
Dallas, TX
Click here to add this to my saved trials
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated:  7/18/2012
1963
mi
from 43215
Garden Grove, CA
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated: 7/18/2012
Vanda Investigational Site
1963
mi
from 43215
Garden Grove, CA
Click here to add this to my saved trials
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated:  7/18/2012
1162
mi
from 43215
Denver, CO
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated: 7/18/2012
Vanda Investigational Site
1162
mi
from 43215
Denver, CO
Click here to add this to my saved trials
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated:  7/18/2012
861
mi
from 43215
Bradenton, FL
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated: 7/18/2012
Vanda Investigational Site
861
mi
from 43215
Bradenton, FL
Click here to add this to my saved trials
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated:  7/18/2012
436
mi
from 43215
Atlanta, GA
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated: 7/18/2012
Vanda Investigational Site
436
mi
from 43215
Atlanta, GA
Click here to add this to my saved trials
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated:  7/18/2012
274
mi
from 43215
Chicago, IL
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated: 7/18/2012
Vanda Investigational Site
274
mi
from 43215
Chicago, IL
Click here to add this to my saved trials
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated:  7/18/2012
622
mi
from 43215
Prairie Village, KA
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated: 7/18/2012
Vanda Investigational Site
622
mi
from 43215
Prairie Village, KA
Click here to add this to my saved trials
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated:  7/18/2012
344
mi
from 43215
Baltimore, MD
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated: 7/18/2012
Vanda Investigational Site
344
mi
from 43215
Baltimore, MD
Click here to add this to my saved trials
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated:  7/18/2012
643
mi
from 43215
Boston, MA
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated: 7/18/2012
Vanda Investigational Site
643
mi
from 43215
Boston, MA
Click here to add this to my saved trials
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated:  7/18/2012
682
mi
from 43215
Omaha, NE
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated: 7/18/2012
Vanda Investigational Site
682
mi
from 43215
Omaha, NE
Click here to add this to my saved trials
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated:  7/18/2012
1756
mi
from 43215
Las Vegas, NV
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated: 7/18/2012
Vanda Investigational Site
1756
mi
from 43215
Las Vegas, NV
Click here to add this to my saved trials
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated:  7/18/2012
467
mi
from 43215
Toms River, NJ
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated: 7/18/2012
Vanda Investigational Site
467
mi
from 43215
Toms River, NJ
Click here to add this to my saved trials
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated:  7/18/2012
480
mi
from 43215
Brooklyn, NY
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated: 7/18/2012
Vanda Investigational Site
480
mi
from 43215
Brooklyn, NY
Click here to add this to my saved trials
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated:  7/18/2012
98
mi
from 43215
Cincinnati, OH
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated: 7/18/2012
Vanda Investigational Site
98
mi
from 43215
Cincinnati, OH
Click here to add this to my saved trials
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated:  7/18/2012
2026
mi
from 43215
Portland, OR
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated: 7/18/2012
Vanda Investigational Site
2026
mi
from 43215
Portland, OR
Click here to add this to my saved trials
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated:  7/18/2012
618
mi
from 43215
Lincoln, RI
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated: 7/18/2012
Vanda Investigational Site
618
mi
from 43215
Lincoln, RI
Click here to add this to my saved trials
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated:  7/18/2012
508
mi
from 43215
Memphis, TN
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated: 7/18/2012
Vanda Investigational Site
508
mi
from 43215
Memphis, TN
Click here to add this to my saved trials
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated:  7/18/2012
1065
mi
from 43215
Austin, TX
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated: 7/18/2012
Vanda Investigational Site
1065
mi
from 43215
Austin, TX
Click here to add this to my saved trials
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated:  7/18/2012
1513
mi
from 43215
Salt Lake City, UT
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated: 7/18/2012
Vanda Investigational Site
1513
mi
from 43215
Salt Lake City, UT
Click here to add this to my saved trials
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated:  7/18/2012
2006
mi
from 43215
Seattle, WA
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated: 7/18/2012
Vanda Investigational Site
2006
mi
from 43215
Seattle, WA
Click here to add this to my saved trials
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated:  7/18/2012
338
mi
from 43215
Brown Deer, WI
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated: 7/18/2012
Vanda Investigational Site
338
mi
from 43215
Brown Deer, WI
Click here to add this to my saved trials
Pilot Trial of CenteringPregnancy With Mindfulness Skills
Integrative Stress Reduction for Maternal-Child Health
Status: Enrolling
Updated:  7/18/2012
2107
mi
from 43215
San Francisco, CA
Pilot Trial of CenteringPregnancy With Mindfulness Skills
Integrative Stress Reduction for Maternal-Child Health
Status: Enrolling
Updated: 7/18/2012
University of California, San Francisco
2107
mi
from 43215
San Francisco, CA
Click here to add this to my saved trials
Yoga for Stress and Mental Health
An 8-Week Hatha Yoga Intervention for Stress and Mental Health
Status: Enrolling
Updated:  7/25/2012
908
mi
from 43215
Dallas, TX
Yoga for Stress and Mental Health
An 8-Week Hatha Yoga Intervention for Stress and Mental Health
Status: Enrolling
Updated: 7/25/2012
Southern Methodist University
908
mi
from 43215
Dallas, TX
Click here to add this to my saved trials
Antidepressant Therapy in Treating Bipolar Type II Major Depression
Treatment of Bipolar Type II Major Depression
Status: Enrolling
Updated:  7/26/2012
414
mi
from 43215
Philadelphia, PA
Antidepressant Therapy in Treating Bipolar Type II Major Depression
Treatment of Bipolar Type II Major Depression
Status: Enrolling
Updated: 7/26/2012
Depression Research Unit - University of Pennsylvania
414
mi
from 43215
Philadelphia, PA
Click here to add this to my saved trials
Ziprasidone Augmentation of SSRIs for Patients With Major Depressive Disorder (MDD) That do Not Sufficiently Respond to Treatment With SSRIs
A Three-phase Study Designed to Test the Efficacy, Tolerability and Safety of the Combination of Ziprasidone With Selective Serotonin Reuptake Inhibitors (SSRI) for Patients With Major Depressive Disorder (MDD) That do Not Sufficiently Respond to Treatment With SSRIs.
Status: Enrolling
Updated:  7/27/2012
643
mi
from 43215
Boston, MA
Ziprasidone Augmentation of SSRIs for Patients With Major Depressive Disorder (MDD) That do Not Sufficiently Respond to Treatment With SSRIs
A Three-phase Study Designed to Test the Efficacy, Tolerability and Safety of the Combination of Ziprasidone With Selective Serotonin Reuptake Inhibitors (SSRI) for Patients With Major Depressive Disorder (MDD) That do Not Sufficiently Respond to Treatment With SSRIs.
Status: Enrolling
Updated: 7/27/2012
Massachusetts General Hospital- Depression Clinical and Research Program
643
mi
from 43215
Boston, MA
Click here to add this to my saved trials
Ziprasidone Augmentation of SSRIs for Patients With Major Depressive Disorder (MDD) That do Not Sufficiently Respond to Treatment With SSRIs
A Three-phase Study Designed to Test the Efficacy, Tolerability and Safety of the Combination of Ziprasidone With Selective Serotonin Reuptake Inhibitors (SSRI) for Patients With Major Depressive Disorder (MDD) That do Not Sufficiently Respond to Treatment With SSRIs.
Status: Enrolling
Updated:  7/27/2012
333
mi
from 43215
Nashville, TN
Ziprasidone Augmentation of SSRIs for Patients With Major Depressive Disorder (MDD) That do Not Sufficiently Respond to Treatment With SSRIs
A Three-phase Study Designed to Test the Efficacy, Tolerability and Safety of the Combination of Ziprasidone With Selective Serotonin Reuptake Inhibitors (SSRI) for Patients With Major Depressive Disorder (MDD) That do Not Sufficiently Respond to Treatment With SSRIs.
Status: Enrolling
Updated: 7/27/2012
Vanderbilt University Medical Center
333
mi
from 43215
Nashville, TN
Click here to add this to my saved trials
Prevention of Relapse & Recurrence of Bipolar Depression
Prevention of Relapse & Recurrence of Bipolar Depression
Status: Enrolling
Updated:  7/27/2012
277
mi
from 43215
Chicago, IL
Prevention of Relapse & Recurrence of Bipolar Depression
Prevention of Relapse & Recurrence of Bipolar Depression
Status: Enrolling
Updated: 7/27/2012
Rush University Medical Center
277
mi
from 43215
Chicago, IL
Click here to add this to my saved trials
Prevention of Relapse & Recurrence of Bipolar Depression
Prevention of Relapse & Recurrence of Bipolar Depression
Status: Enrolling
Updated:  7/27/2012
414
mi
from 43215
Philadelphia, PA
Prevention of Relapse & Recurrence of Bipolar Depression
Prevention of Relapse & Recurrence of Bipolar Depression
Status: Enrolling
Updated: 7/27/2012
Depression Research Unit
414
mi
from 43215
Philadelphia, PA
Click here to add this to my saved trials
Integrated Treatment for Comorbid Depression and Obesity in Adolescents
Integrated Treatment for Comorbid Depression and Obesity in Adolescents
Status: Enrolling
Updated:  7/28/2012
619
mi
from 43215
Providence, RI
Integrated Treatment for Comorbid Depression and Obesity in Adolescents
Integrated Treatment for Comorbid Depression and Obesity in Adolescents
Status: Enrolling
Updated: 7/28/2012
Brown University
619
mi
from 43215
Providence, RI
Click here to add this to my saved trials
Quetiapine in Melancholic Depression
Quetiapine in Melancholic Depression: an fMRI Study of Treatment-induced Changes in the Neurocircuitry of the Stress Response
Status: Enrolling
Updated:  7/31/2012
98
mi
from 43215
Cincinnati, OH
Quetiapine in Melancholic Depression
Quetiapine in Melancholic Depression: an fMRI Study of Treatment-induced Changes in the Neurocircuitry of the Stress Response
Status: Enrolling
Updated: 7/31/2012
University of Cincinnati
98
mi
from 43215
Cincinnati, OH
Click here to add this to my saved trials
Safety, Efficacy and Tolerability of Vilazodone in Major Depressive Disorder
A Double-Blind, Placebo-Controlled, Fixed-Dose Study of Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated:  8/20/2012
1959
mi
from 43215
Orange, CA
Safety, Efficacy and Tolerability of Vilazodone in Major Depressive Disorder
A Double-Blind, Placebo-Controlled, Fixed-Dose Study of Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated: 8/20/2012
Forest Investigative Site 009
1959
mi
from 43215
Orange, CA
Click here to add this to my saved trials
Safety, Efficacy and Tolerability of Vilazodone in Major Depressive Disorder
A Double-Blind, Placebo-Controlled, Fixed-Dose Study of Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated:  8/20/2012
1928
mi
from 43215
Riverside, CA
Safety, Efficacy and Tolerability of Vilazodone in Major Depressive Disorder
A Double-Blind, Placebo-Controlled, Fixed-Dose Study of Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated: 8/20/2012
Forest Investigative Site 005
1928
mi
from 43215
Riverside, CA
Click here to add this to my saved trials